ImmuneRegen BioSciences, Inc. Announces First Study Of Viprovex(TM) To Explore Adjuvant Capabilities In The Area Of Pandemic Influenza Vaccine

January 6, 2007 – 7:52 pm | posted in Bird Flu / Avian Flu, Immune System

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced it has commenced the first study of Viprovex(TM) to explore its adjuvant capabilities in the area of Pandemic Influenza Vaccine. The study is being conducted in conjunction with privately-held vaccine developer GenPhar, Inc., of Charleston, SC. GenPhar began its biodefense program in 2000 as one of the first in the industry and now works closely with the Department of Defense. GenPhar has vaccines for lethal viruses such as Ebola, Marburg, dengue and influenza, with several approaching the final development and testing stages prior to approval.

“We are very happy to announce our relationship with GenPhar which has developed a promising portfolio of vaccines and are excited to begin generating data in this very relevant area. If we can confirm immunostimulatory adjuvant activity in conjunction with an effective vaccine against Avian Influenza, we can help vaccinate many more Americans helping limited amounts of vaccine provide more effective, perhaps global coverage,” said ImmuneRegen’s CEO Michael Wilhelm. “GenPhar’s vaccine development program is aggressively achieving milestones against viruses such as HIV, hepatitis B and C virus, influenza, and potential bioterror agents such as the hemorrhagic fevers caused by Ebola and Marburg virus, and dengue fever. We are very pleased to be working with such a well-established and respected scientific team, and believe that positive results with Viprovex(TM) will also open up the possibilities to include Viprovex(TM) into other vaccines against diseases with great social and economical impacts, such as HIV and hepatitis C and can be followed up with additional studies further demonstrating adjuvant capabilities.”

ShareThis

Also Read

  • European Medicines Agency Adopts First Positive Opinion For Mock-up Pandemic Influenza Vaccine
  • EMEA Recommends Authorisation Of First Pre-Pandemic Influenza Vaccine, Europe
  • Government Announces Advanced Supply Contracts For Pandemic Flu Vaccine, UK
  • Antigen Sparing Adjuvant Strategy Might Increase Avian Flu Vaccine Production
  • Statement By Mike Leavitt, Secretary Of HHS, On Approval Of First U.S. Vaccine For Humans Against The Avian Influenza Virus H5N1
  • Vical’s Vaxfectin(TM) Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
  • HHS Announces $75 Million In Supplemental Funding To States For Pandemic Flu Preparedness
  • Experimental Flu Vaccine Appears Promising In Early Tests
  • Vical Expands Testing Of Vaxfectin(TM) Adjuvant To U.S. Navy Malaria Vaccine Program
  • Baxter Reveals Interim Results On Pandemic Flu Vaccine Clinical Trial

    • You must be logged in to post a comment.